KRAS and colorectal cancer: To experimentally address this hypothesis – using the three cell lines modelling wild-type and KRAS and BRAF mutant colorectal cancer – the cells were treated with abemaciclib, a clinically approved CDK4/6 inhibitor, also known to arrest cell cycle in the G1/G0 phases21.